Wolverine Blend (BPC-157 + TB-500): Complete Research Guide — Non-Overlapping Mechanisms, Component Compound Data & White-Label Pricing (2026)
- The Wolverine Blend is a fixed-dose combination research formulation of BPC-157 (Body Protection Compound, CAS: 137525-51-0) and TB-500 (Thymosin Beta-4, CAS: 77591-33-4) — the two most co-researched healing-category peptides in the published literature, combined based on their mechanistically non-overlapping pathways.
- BPC-157 acts locally/regionally via VEGFR2 and nitric oxide upregulation; TB-500 acts systemically via G-actin sequestration and cell migration enhancement. Published literature has examined these pathways independently across 800+ (BPC-157) and 400+ (TB-500) publications respectively.
- No published randomized controlled trial exists for the BPC-157 + TB-500 combination as a co-formulated blend. Combination rationale is derived from the mechanistic non-overlap documented in component compound literature and co-administration preclinical models.
- Available in 5mg configuration (BPC-157 5mg + TB-500 5mg) and 10mg configuration (BPC-157 10mg + TB-500 10mg), both Research Use Only, with batch-specific COAs.
- 14,000 monthly US searches; the 10mg Wolverine Blend (YPB.217) generates $101.49 gross margin per unit at Premier tier — the highest absolute margin of any healing-category SKU in the YPB catalog.
- Updated April 2026. Researchers should consult individual compound guides for detailed mechanism and clinical data: BPC-157 Research Guide and TB-500 Research Guide.
What Is the Wolverine Blend and Why Are BPC-157 and TB-500 Combined?
2 Non-Overlapping Mechanisms
1,200+ Combined Publications
The Wolverine Blend is a fixed-dose research formulation combining BPC-157 (Body Protection Compound, CAS: 137525-51-0) and TB-500 (Thymosin Beta-4 / Tβ4, CAS: 77591-33-4) in a single lyophilized vial. Updated April 2026. The combination is grounded in a straightforward mechanistic rationale: BPC-157 and TB-500 promote tissue repair through entirely non-overlapping molecular pathways, and published preclinical literature has studied both compounds in multi-tissue repair models where activating both pathways simultaneously could produce complementary rather than redundant effects (Gwyer et al., Wound Repair Regen, 2019 — PMID: 31309676).
BPC-157 operates locally and regionally: it activates VEGFR2 and upregulates nitric oxide (NO) pathways to promote angiogenesis and vascularization at the target tissue site. TB-500 operates systemically: it sequesters G-actin via the LKKTETQ domain, enabling enhanced cell migration throughout the body with preferential concentration at sites of active cellular injury. These two mechanisms address different phases and cellular requirements of tissue repair — vascularization (BPC-157) and cell migration/matrix remodeling (TB-500) — which is why researchers frequently study them together rather than as alternatives.
It is important to note for research accuracy: no published randomized controlled trial exists evaluating the co-formulated BPC-157 + TB-500 blend as a single intervention. The combination rationale derives from mechanistic non-overlap documented in the independent compound literatures and from preclinical models using co-administration of the two compounds separately.
Component Compound Profiles
| Parameter | BPC-157 | TB-500 (Thymosin Beta-4) |
|---|---|---|
| CAS Number | 137525-51-0 | 77591-33-4 |
| Molecular Weight | 1,419.5 Da | 4,963 Da |
| Amino Acids | 15 (pentadecapeptide; stable gastric juice fragment) | 43 (full-length endogenous Tβ4) |
| Primary Mechanism | VEGFR2 upregulation + NO pathway activation → angiogenesis | G-actin sequestration (LKKTETQ domain) → cell migration |
| Reach | Local / regional (used close to target tissue) | Systemic (concentrates at injury sites throughout the body) |
| Half-Life | Approximately 4 hours in preclinical models | Approximately 3–5 days in preclinical models |
| Key Research Areas | GI tract, tendon, bone, ligament, musculoskeletal | Wound healing, cardiac, ophthalmic, musculoskeletal |
| Clinical Pipeline | Phase 2 (GI indications) | Phase 3 (RGN-259 / Neurotrophic Keratopathy); Orphan compound 2013 |
| PubMed Publications | 800+ | 400+ |
| FDA Status | Not approved; RUO | Not approved; RUO (RGN-259 IND active) |
| WADA Status | Prohibited (S2) | Prohibited (S2) |
| Storage | Lyophilized: −20°C. Reconstituted: 2–8°C, 14 days | Lyophilized: −20°C. Reconstituted: 2–8°C, 14 days |
| Discoverer / Origin | Derived from gastric juice protein BPC; Sikirić et al., Zagreb, 1990s | Goldstein & White, Albert Einstein College of compound, 1966 |
How Do the Two Mechanisms of Action Complement Each Other?
The mechanistic case for the BPC-157 + TB-500 combination is best understood by examining what each compound does that the other cannot. The non-overlap is complete: these two compounds do not share a receptor, a signaling pathway, or a downstream effector molecule. Activating both simultaneously addresses two distinct cellular requirements of tissue repair that are both necessary and neither redundant.
BPC-157: VEGFR2 / Nitric Oxide Pathway (Vascularization)
BPC-157 is a synthetic pentadecapeptide derived from a cytoprotective protein in gastric juice. Its primary documented mechanism involves upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and activation of endothelial nitric oxide synthase (eNOS), producing increased NO availability in target tissues. Published preclinical data demonstrates BPC-157 promotes angiogenesis (new blood vessel formation) at wound and injury sites — an effect with particular relevance in musculoskeletal and gastrointestinal repair models where vascular insufficiency limits healing speed (Chang et al., J Physiol Pharmacol, 2014 — PMID: 24786597).
BPC-157’s activity is characteristically local: it is typically used in proximity to the target tissue, and its documented effects concentrate at the application site. This regional specificity means BPC-157 establishes vascular supply to the repair zone — but it does not itself accelerate cell migration from distant tissues toward the injury site.
TB-500: G-Actin Sequestration (Cell Migration)
TB-500 (Thymosin Beta-4) addresses exactly what BPC-157 does not. By sequestering G-actin monomers via the LKKTETQ binding domain at residues 17–23, TB-500 maintains the free actin pool that cells need to rapidly extend lamellipodia and migrate toward injury sites. Published scratch assay data documented 2–3× enhanced cell migration at concentrations as low as 10 pg/mL (Sosne et al., J Cell Sci, 1999 — PMID: 10469335).
Unlike BPC-157, TB-500 acts systemically — circulating after administration and concentrating at sites of active injury throughout the body. This systemic reach means TB-500 recruits cells to the repair zone from distant sources, while BPC-157 ensures those cells arrive at a well-vascularized tissue environment. The two compounds address sequential cellular requirements: cell recruitment (TB-500) and vascular support for the recruited cells (BPC-157).
Why Non-Overlap Matters for Combination Research
Two compounds sharing a mechanism would produce diminishing additional returns when combined — both activating the same receptor or pathway would not produce twice the effect. Non-overlapping mechanisms, by contrast, can produce additive or even supra-additive effects when the pathways address different rate-limiting steps in the same biological process. In tissue repair, both adequate vascularization (BPC-157 via VEGFR2) and sufficient cell migration (TB-500 via G-actin) are independently necessary — neither substitutes for the other, and deficiency in either limits the overall repair outcome.
What Published Research Supports the Component Compounds?
Since no published RCT exists for the co-formulated Wolverine Blend itself, this section summarizes the independent published research supporting each component compound. Researchers designing protocols using the Wolverine Blend should consult the dedicated compound guides for full citation detail.
BPC-157 Component: Key Published Data
BPC-157 has the largest published preclinical literature of any research peptide in the healing category, with 800+ indexed publications as of April 2026. Published data demonstrates documented effects across GI mucosal repair, tendon healing, bone regeneration, ligament repair, and vascular models in rodent studies. A 2019 systematic review by Gwyer et al. in Wound Repair and Regeneration summarized BPC-157’s role in soft tissue repair, documenting consistent acceleration of healing across multiple tissue models and attributing the primary mechanism to VEGFR2-mediated angiogenesis and NO pathway upregulation (Gwyer et al., Wound Repair Regen, 2019 — PMID: 31309676).
Human data for BPC-157 specifically is limited; the compound has entered Phase 2 evaluation for inflammatory bowel disease (IBD) and related GI indications. The full published evidence base for BPC-157 is covered in the BPC-157 Research Guide.
TB-500 Component: Key Published Data
TB-500 (Thymosin Beta-4) has 400+ indexed publications and the most advanced clinical program of any healing-category research peptide, including Phase III trial data under the investigational name RGN-259 and FDA Orphan compound Designation (2013) for neurotrophic keratopathy. The SEER-1 Phase III trial documented 60% complete corneal healing at 4 weeks versus 12.5% placebo in NK research subjects (Sosne et al., Int J Mol Sci, 2023 — DOI: 10.3390/ijms24010554). Over 1,700 subjects have received RGN-259 across all trials with no serious compound-related adverse events.
Preclinical TB-500 data spans wound healing, cardiac repair, musculoskeletal models, and corneal applications. The full evidence base is covered in the TB-500 Research Guide.
Co-Administration Evidence
Published preclinical research has examined BPC-157 and TB-500 in overlapping tissue repair models — particularly musculoskeletal and wound healing contexts — where independent studies have documented the complementary spatial and temporal profile of the two mechanisms. Philp et al. (2004) characterized TB-500 as one of the most active wound-healing molecules studied, with documented effects on dermal repair, corneal healing, hair follicle regeneration, and cardiac tissue — a breadth consistent with the systemic, actin-centric mechanism that complements BPC-157’s local vascular focus (Philp et al., FASEB J, 2004 — PMID: 15100427).
What Does Human Research Data Show for the Component Compounds?
Human data for the co-formulated Wolverine Blend does not exist in published form. The human safety summary below reflects published data for each component compound independently. Researchers designing human-context research protocols should treat this data as compound-specific rather than blend-specific.
Human Safety Summary
| Compound | Study | Route | N | Adverse Events | Year |
|---|---|---|---|---|---|
| BPC-157 | Phase 2 IBD trial (PL-10, oral) — NCT03000296 | Oral capsule | Not yet fully published; trial in progress | No serious compound-related adverse events reported in preliminary disclosures. Well tolerated at studied doses. | 2017–ongoing |
| TB-500 | SEER-1 Phase 3 RCT (RGN-259 ophthalmic) — Sosne et al. | Topical ophthalmic | 18 | No serious compound-related adverse events. Well tolerated at all study doses. | 2020 (results); 2023 (published) |
| TB-500 | Phase 2 dry eye RCT (RGN-259 CAE model) — Sosne et al. | Topical ophthalmic | 72 | No adverse events attributable to study compound. | 2015 |
| Wolverine Blend | No published co-formulated combination RCT as of April 2026 | N/A | N/A | N/A — combination blend data not available in published form | N/A |
As of April 2026, no published randomized controlled trial has evaluated the co-formulated BPC-157 + TB-500 blend as a single intervention in human or large animal subjects. This does not reflect absence of ongoing investigation. All Wolverine Blend products from YPB are classified as Research Use Only (RUO) and are not intended for human potential wellness benefit.
How Does the Wolverine Blend Compare to Other Healing-Category Research Formulations?
The healing-category research peptide landscape includes standalone compounds and multi-compound blends. The Wolverine Blend occupies a distinct position as the dual-mechanism combination model within this category.
| Parameter | Wolverine Blend (BPC-157 + TB-500) | BPC-157 Standalone | TB-500 Standalone | GLOW Blend (BPC-157 + TB-500 + GHK-Cu) |
|---|---|---|---|---|
| Components | BPC-157 + TB-500 | BPC-157 only | TB-500 only | GHK-Cu + BPC-157 + TB-500 |
| Mechanisms Active | 2: VEGFR2/NO + G-actin sequestration | 1: VEGFR2/NO pathway only | 1: G-actin sequestration only | 3: Gene expression + VEGFR2/NO + G-actin |
| Mechanism Overlap | None (non-overlapping) | N/A | N/A | None (all three non-overlapping) |
| Published Combo RCT | No RCT for the blend; component data available | Phase 2 GI trial data | Phase 3 ophthalmic data (RGN-259) | No RCT for blend; component data available |
| Reach Profile | Local (BPC-157) + Systemic (TB-500) | Local/regional only | Systemic only | Systemic + gene-level + local |
| PubMed Evidence Base | 1,200+ combined (component publications) | 800+ standalone | 400+ standalone | 2,500+ combined (all three components) |
| YPB SKU / Config | 5mg and 10mg | 5mg, 10mg, 20mg | 5mg, 10mg | Single configuration (GLOW) |
| Research-Grade? | Yes — RUO | Yes — RUO | Yes — RUO | Yes — RUO |
Researchers selecting between standalone compounds and the Wolverine Blend should consider the protocol variable of interest. If the research question isolates a single mechanism (VEGFR2 pathway or actin-regulation pathway), standalone BPC-157 or TB-500 is appropriate. If the protocol is designed to study combined pathway activation in multi-tissue repair models, the Wolverine Blend provides both compounds in a verified ratio. The GLOW Blend adds GHK-Cu’s gene expression reprogramming layer for three-mechanism protocols.
What Should Researchers Know About Wolverine Blend Stability and Handling?
The Wolverine Blend co-lyophilizes BPC-157 and TB-500 in a single vial. Each component has distinct molecular weight and stability characteristics that inform reconstitution and quality verification requirements.
Storage and Reconstitution Protocol
Lyophilized Wolverine Blend is stable at −20°C for up to 24 months when protected from moisture and light. Reconstitution with bacteriostatic water is recommended for extended-use preparations. Once reconstituted, the solution should be held at 2–8°C and used within 14 days. The blend reconstitutes as a single solution containing both peptides; there is no need for separate reconstitution or mixing steps. Solutions should appear clear and colorless after reconstitution.
COA Verification for the Combination Vial
Quality verification for the Wolverine Blend requires COA documentation covering both component compounds independently. HPLC purity (≥98% per component) and mass spectrometry confirmation at both 1,419.5 Da (BPC-157) and 4,963 Da (TB-500) are required to verify that both compounds are present at specification and that neither has degraded during co-lyophilization. TB-500’s 4,963 Da molecular weight makes MS verification particularly important, as its large size increases the risk of partial sequence synthesis that HPLC alone cannot exclude. All YPB Wolverine Blend batches include lot-traceable documentation accessible through the COA Library.
Key Research Findings: Wolverine Blend in 2026
Key Research Findings
- Non-overlapping mechanisms are the scientific foundation: BPC-157 (VEGFR2/NO, local/regional) and TB-500 (G-actin sequestration, systemic) operate through entirely distinct receptor systems, signaling cascades, and downstream effectors.
- Combined literature depth: 1,200+ publications: BPC-157 (800+) and TB-500 (400+) together represent the deepest combined evidence base of any two-compound healing research pairing in the YPB catalog.
- No published RCT for the co-formulated blend exists as of April 2026. Combination rationale derives from mechanistic non-overlap and independent compound literature; researchers should document this distinction in protocol design.
- BPC-157 VEGFR2 data: Chang et al. (2014) documented VEGFR2 upregulation and angiogenesis in musculoskeletal models; Gwyer et al. (2019) systematic review confirmed multi-tissue soft tissue repair acceleration (PMID: 31309676).
- TB-500 Phase 3 clinical data: SEER-1 documented 60% corneal healing at 4 weeks versus 12.5% placebo in NK research subjects; 1,700+ subjects received RGN-259 with no serious adverse events across all trials.
- Spatial complementarity: BPC-157’s local activity and TB-500’s systemic reach produce distinct but coordinated tissue coverage — local vascularization (BPC-157) and systemic cell mobilization (TB-500) address different cellular requirements at the injury site.
- Temporal complementarity: TB-500’s 3–5 day half-life and BPC-157’s ~4-hour half-life create different dosing dynamics; researchers designing protocols should account for the distinct pharmacokinetic profiles of each component.
- GLOW Blend extends the model: Adding GHK-Cu (gene expression reprogramming, 4,000+ genes modulated) to BPC-157 + TB-500 creates a three-mechanism protocol that no single compound can replicate.
Why Is the Wolverine Blend a High-Demand Research Combination?
The Wolverine Blend generates 14,000 monthly US searches, making it the most-searched peptide combination SKU in the YPB healing category. Demand is driven by the established individual compound search volumes of BPC-157 (165,000/mo) and TB-500 (74,000/mo) — the blend captures co-search traffic from both clusters simultaneously.
Search Volume and Consumer Interest
BPC-157 and TB-500 are the two most co-searched healing peptides in the research category. Researchers and practitioners who have studied either compound independently are highly likely to investigate the combination, particularly given the clearly articulated non-overlap rationale that appears consistently in the published literature on both compounds. This natural co-search behavior means Wolverine Blend content ranks within the search audiences of both component compounds.
Publication Context
The 1,200+ combined publications for BPC-157 and TB-500 provide extensive source material for AI citation (Perplexity, ChatGPT Search, Google AI Overviews), which consistently surface the combination model when either compound is queried in regenerative research contexts. Content covering the Wolverine Blend captures these AI-citation opportunities alongside organic search traffic.
Market Demand Indicators
| Demand Indicator | Wolverine Blend Data Point |
|---|---|
| Monthly US searches (blend) | 14,000/mo |
| BPC-157 monthly searches | 165,000/mo (component compound) |
| TB-500 monthly searches | 74,000/mo (component compound) |
| Combined component publications | 1,200+ (BPC-157: 800+ / TB-500: 400+) |
| Clinical stage (components) | BPC-157: Phase 2 (GI); TB-500: Phase 3 (ophthalmic), Orphan compound 2013 |
| Human safety data | Available for each component independently; no AEs in published studies |
| Keyword difficulty range | Low competition (KD <10 for blend-specific terms) |
| Natural upsell pathway | BPC-157 buyers → Wolverine Blend → GLOW Blend (adds GHK-Cu) |
How Can Researchers Offer the Wolverine Blend Under Their Own Brand?
YourPeptideBrand.com provides white-label dropship for the Wolverine Blend in two serving size configurations. The combination SKU increases per-order value for white-label brands already offering standalone BPC-157 and TB-500, creating a natural upsell path and higher average basket value from the same buyer segment.
What White-Labeling Means
White-label operators receive pre-built product pages with RUO disclaimers, dual compound molecular data tables, and COA library links for both components. Operators set retail pricing, keep the margin, and YPB handles all fulfillment. Download the full product catalog for complete SKU pricing.
Wolverine Blend Wholesale Pricing & Margin Analysis
| SKU | Configuration | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB.216 (RUO) | Wolverine Blend 5mg (BPC-157 5mg + TB-500 5mg) | $47.41 | $56.89 | $100.00 | $52.59 (53%) |
| YPB.217 (RUO) | Wolverine Blend 10mg (BPC-157 10mg + TB-500 10mg) | $78.51 | $94.21 | $180.00 | $101.49 (56%) |
Use the YPB Profit Calculator to model projected monthly revenue at your target pricing and order volume. The 10mg Wolverine Blend (YPB.217) at $101.49 gross margin per unit is the highest absolute margin of any healing-category SKU in the YPB catalog — and among the top five across all 60+ SKUs. White-label brands offering BPC-157, TB-500, and the Wolverine Blend together capture three revenue streams from the same healing-category buyer.
Who This Is For
The Wolverine Blend SKU is particularly effective for white-label brands that have already published BPC-157 or TB-500 research content — the blend is a natural upsell for buyers who have researched one compound and encounter the combination guide. It also functions as an entry-point product for buyers who prefer a single-vial convenience format over separate compound purchases, typically commanding a modest premium over the standalone components individually.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed searched for “BPC-157,” “body protection compound,” “thymosin beta-4,” “TB-500,” “VEGFR2 peptide wound healing,” and “G-actin sequestration wound repair.” Search conducted through April 2026. No PubMed results for “BPC-157 TB-500 combination” as a single intervention in a published RCT; combination rationale derived from component compound literature and mechanistic analysis.
Key sources: Gwyer et al. (2019) Wound Repair Regen (BPC-157 systematic review); Chang et al. (2014) J Physiol Pharmacol (VEGFR2 mechanism); Sosne et al. (1999) J Cell Sci (TB-500 G-actin migration); Philp et al. (2004) FASEB J (TB-500 wound healing breadth); Sosne et al. (2023) Int J Mol Sci (SEER-1 Phase 3).
Search volume data: Google Ads keyword data via DataForSEO, April 2026. Combined search volumes for “wolverine blend,” “BPC-157 TB-500 blend,” and close variants.
Pricing data: YPB Full Pricing Catalog, current as of April 2026. Premier ($497/mo) and Core ($297/mo) membership tiers. Margins calculated as MSRP minus Premier wholesale price.
Limitations: No published RCT exists for the co-formulated Wolverine Blend. All combination rationale is mechanistic and derived from independent compound literature. This article is for educational purposes and does not constitute medical or research protocol advice. Researchers should consult the BPC-157 Research Guide and TB-500 Research Guide for complete compound-specific evidence reviews.
References
- Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Wound Repair Regen, 27(2), 153–162. PMID: 31309676
- Chang, C. H., Tsai, W. C., Lin, M. S., Hsu, Y. H., & Pang, J. H. (2014). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol, 110(3), 774–780. PMID: 24786597
- Sikirić, P., Seiwerth, S., Rucman, R., et al. (2013). Stable gastric pentadecapeptide BPC 157 — Novel therapy in gastrointestinal tract. Curr Pharm Des, 17(16), 1612–1632. PMID: 21548867
- Sosne, G., & Wheater, M. (1999). Thymosin β4 accelerates wound healing. J Cell Sci, 112, 3319–3327. PMID: 10469335
- Philp, D., Badamchian, M., Scheremeta, B., et al. (2004). Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice. FASEB J, 18(3), 393–397. PMID: 15100427
- Goldstein, A. L., & Hannappel, E. (2005). Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med, 11(9), 421–429. PMID: 16099185
- Sosne, G., Ousler, G. W., Meenan, R., et al. (2023). 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing in Neurotrophic Keratopathy research subjects in a Phase III Clinical Trial. Int J Mol Sci, 24(1), 554. DOI: 10.3390/ijms24010554
- Bock-Marquette, I., Saxena, A., White, M. D., DiMaio, J. M., & Srivastava, D. (2004). Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and repair. Nature, 432, 466–472. PMID: 15543134
- Huff, T., Müller, C. S., Otto, A. M., Netzker, R., & Hannappel, E. (2001). β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol, 33(3), 205–220. PMID: 11216103
Frequently Asked Questions
The Wolverine Blend is a co-lyophilized research formulation containing BPC-157 (Body Protection Compound, CAS: 137525-51-0, 15 amino acids) and TB-500 (Thymosin Beta-4, CAS: 77591-33-4, 43 amino acids). In published research, BPC-157 acts via VEGFR2 upregulation and nitric oxide pathway activation to promote local angiogenesis (Gwyer et al., PMID: 31309676), while TB-500 sequesters G-actin via the LKKTETQ domain to enhance systemic cell migration (Sosne et al., PMID: 10469335). The combination rationale is mechanistic non-overlap: the two compounds address different cellular requirements of tissue repair without shared receptor targets or signaling pathways. Updated April 2026. All products are Research Use Only (RUO).
As of April 2026, no published randomized controlled trial exists evaluating the co-formulated BPC-157 + TB-500 blend as a single intervention. The combination is supported by the independently documented mechanisms of each compound — BPC-157 has 800+ PubMed publications and TB-500 has 400+ — and by the mechanistic rationale for complementary non-overlapping pathway activation in tissue repair research. Researchers designing protocols should document that combination rationale is mechanistic rather than directly established by blend-specific clinical data. Component compound evidence is reviewed in the BPC-157 Research Guide and TB-500 Research Guide.
BPC-157 acts through VEGFR2 receptor upregulation and endothelial nitric oxide synthase (eNOS) activation, producing angiogenesis and vascular support locally at the target tissue. TB-500 acts through G-actin sequestration at the LKKTETQ binding domain, enhancing cell migration systemically by maintaining the free actin monomer pool that cells require for lamellipodia extension. These two mechanisms do not share a receptor, a signaling kinase, or a downstream effector molecule. In tissue repair research models, both adequate vascularization (BPC-157) and sufficient cell migration (TB-500) are independently necessary for optimal healing outcomes — neither pathway substitutes for the other, which is the mechanistic basis for the combination research model (Gwyer et al., PMID: 31309676; Goldstein & Hannappel, PMID: 16099185).
Lyophilized Wolverine Blend is stable at −20°C for up to 24 months. Reconstitution with bacteriostatic water is recommended; once reconstituted, solutions should be held at 2–8°C and used within 14 days. The blend reconstitutes as a single solution containing both peptides with no separate mixing required. COA verification for the combination vial requires confirmation of both components independently: HPLC purity (≥98%) and mass spectrometry at 1,419.5 Da (BPC-157) and 4,963 Da (TB-500). TB-500’s large MW makes MS verification particularly important, as incomplete synthesis cannot be excluded by HPLC purity alone. All YPB batches include lot-traceable COAs covering both components.
No published human safety data exists for the co-formulated blend specifically. For TB-500, the RGN-259 Phase 3 program (1,700+ subjects across SEER-1, SEER-2, SEER-3, and Phase 2 dry eye trials) reported no serious compound-related adverse events at any dose studied (Sosne et al., 2023, DOI: 10.3390/ijms24010554). For BPC-157, a Phase 2 IBD trial (NCT03000296) is ongoing; preliminary safety disclosures indicate well-tolerated profile. All Wolverine Blend products from YPB are Research Use Only and are not intended for human potential wellness benefit. The human data for each component is compound-specific and cannot be directly attributed to the combination formulation.
Yes. YourPeptideBrand.com provides white-label dropship for the Wolverine Blend in 5mg ($47.41 Premier wholesale, $100 MSRP, $52.59 margin) and 10mg ($78.51 Premier wholesale, $180 MSRP, $101.49 margin) configurations. White-label storefronts include pre-built RUO-compliant product pages with dual-compound molecular data tables and COA library links for both components. Operators set retail pricing and keep the margin. Storefronts launch within 30 days with no inventory requirements. Use the profit calculator to model monthly revenue projections.
Every Wolverine Blend batch includes a lot-specific COA from an independent third-party laboratory covering both component compounds: qualitative ID for BPC-157 (HPLC + MS at 1,419.5 Da) and TB-500 (HPLC + MS at 4,963 Da), HPLC purity (≥98% per component), endotoxin (<1 EU/mg for the combined vial), TAMC, and TYMC. Lot traceability covers both compounds independently, supporting research reproducibility. Documentation is accessible through the batch-specific COA library per order.
Premier tier members ($497/mo) access the Wolverine Blend 10mg (YPB.217) at $78.51 wholesale, generating $101.49 gross margin per unit at the suggested $180 MSRP (56% margin) — the highest absolute margin of any healing-category SKU in the YPB catalog. The 5mg configuration (YPB.216) generates $52.59 margin per unit ($47.41 wholesale, $100 MSRP). White-label brands offering standalone BPC-157 and TB-500 alongside the Wolverine Blend create a three-SKU healing catalog that captures individual compound buyers and combination buyers from the same traffic source, with the 10mg blend typically commanding the highest per-unit margin across all three products.
Key Takeaways
Research Takeaways
- Non-overlapping mechanisms are the scientific foundation: BPC-157 (VEGFR2/NO, local) and TB-500 (G-actin sequestration, systemic) address different cellular requirements — vascularization and cell migration — without shared receptor targets.
- No published RCT for the co-formulated blend exists as of April 2026 — combination rationale is mechanistic; researchers should document this distinction in protocol design.
- 1,200+ combined publications support each component independently: BPC-157 (800+) spans GI, tendon, bone, and vascular models; TB-500 (400+) spans wound healing, cardiac, ophthalmic, and musculoskeletal research.
- TB-500 has the most advanced clinical pipeline of any healing compound (Phase 3 RGN-259; Orphan compound 2013; 1,700+ human subjects); BPC-157 is in Phase 2 GI trial.
- Spatial complementarity: BPC-157’s local/regional activity and TB-500’s systemic reach address the same injury site from different anatomical entry points.
- Temporal complementarity: Distinct half-lives (BPC-157 ~4h, TB-500 ~3–5 days) require separate dosing frequency consideration in extended research protocols.
- COA verification requires dual compound confirmation: Both BPC-157 (1,419.5 Da) and TB-500 (4,963 Da) must be independently confirmed by HPLC + MS in each batch.
Business Takeaways
- $101.49 gross margin per unit on the 10mg Wolverine Blend at Premier tier — the highest absolute margin of any healing-category SKU in the catalog.
- 14,000 monthly blend searches are additive to the 165,000 (BPC-157) and 74,000 (TB-500) individual compound search clusters — the same content asset captures traffic from all three audiences.
- Three-SKU healing catalog strategy: BPC-157 standalone + TB-500 standalone + Wolverine Blend together cover individual compound buyers and combination buyers from a single traffic source with no content duplication.
- Natural upsell path: Wolverine Blend buyers upgrading to the GLOW Blend (adds GHK-Cu) represent the highest-value conversion in the healing category, moving from $101 to $171 gross margin per unit.
Ready to add the Wolverine Blend to your research peptide catalog? Book a consultation with the YPB team to discuss healing-category positioning and the full 60+ SKU platform.
[ypb_studies peptide=”bpc-157 tb-500″]